How Do Doctors Self-Refer?

In my full-time clinical practice days, other practitioners often referred patients to me for accidental findings on x-rays, ultrasounds, or MRI exams. Sometimes a patient would have had a CT scan of her abdomen that revealed an asymptomatic tumor inside her adrenal gland. More often, an ultrasound of the carotid arteries or an MRI of the spine uncovered a mass within the thyroid gland. This phenomenon is so common that these discoveries have a name: “incidentalomas.” Never accuse doctors of not being wordsmiths.

For thyroid incidentalomas, I would usually drag a portable ultrasound machine into the patient’s room and get a quick look at the lesion with my own eyes. Through reasonably straightforward criteria, the patient and I could choose whether or not to biopsy, to repeat an ultrasound in a year or two, or to forget we ever saw the lesion. I never charged extra for these informal bedside exams. I considered this particular use of the ultrasound machine akin to a 21st-century stethoscope. I wouldn’t charge a patient an additional fee for listening to her heart or lungs, so it didn’t seem proper to charge them for this use of ultrasound. That wasn’t charity on my part; this philosophy is becoming so prevalent as to have guidelines crop up around it.

But sometimes, I saw features in a thyroid nodule or a lymph node that made me think the lesion should be biopsied, usually by me. And I was paid well for these procedures (technically, the University of Kansas was well-paid since I was salaried. I made the same amount of money whether I did the procedure or not). A thyroid biopsy, which takes maybe ten minutes, pays about the same amount as caring for a diabetic patient for a year (thank the RUC). The revenue from diagnostic studies comes not only from the professional fee, which pays the doctor for her interpretation and consulting regarding the study but also from a “facility fee” meant to cover technical costs surrounding the maintenance and use of special equipment. A physician who owns the equipment needed to perform labs or imaging can profit by collecting both of these fees. So the incentive for me or any other doctor to do imaging or procedures in our own practices–so-called “physician self-referral”–is considerable.

Stark laws arose a few decades ago to discourage physician self-referral and kickbacks from referrals to other physicians, but they made specific exceptions to allow “necessary testing” in physician offices. Once upon a time, the American Medical Association Code of Ethics prohibited doctors from owning imaging or lab equipment. The AMA said doctors should not have a financial interest in testing. But that rule eventually changed, and now, the AMA is much softer on physician-owned testing, insisting only that doctors make diagnostic and treatment decisions without taking financial issues into account. The trouble is, from a financial standpoint, that philosophy probably doesn’t work.

Doctors are human, and physician-owned imaging and lab centers unequivocally appear to drive up the cost of care by increasing the likelihood of getting additional procedures without improving outcomes. In a tiny sample of the literature on this topic, a group of researchers has shown that MRI scans of the neck, lower back, knee, and shoulder, when performed in physician-owned machines, are much more likely to be normal, indicating overuse by the physicians who own the machines and bill for their use. Multiple studies show that physician-owned hospitals are associated with an increase in spending without a corresponding increase in quality, a phenomenon that leaks into the outpatient setting as well. For example, physicians, particularly those treating immune or malignant diseases, routinely sell drugs to their patients at a small markup. Some physicians make more of their income from such practices than they do by seeing patients. Their incentive is naturally toward using more expensive drugs, whether they consciously intend to or not.

This is the part of the post where I propose a brilliant policy strategy. Except I’m not sure there is one, apart from the transparency rules we’ve discussed at length on this blog. Physician-owned testing, after all, does come with some benefits. Patients can often get the test performed on the same day and in the same location. Since doctors are so powerful, there’s likely not a movement afoot to take their radiology machines away.

But by using more direct contracting with physicians, we could limit the incentive for doctors to overuse certain diagnostic and therapeutic procedures. If I had been paid a flat monthly rate to take care of the endocrine needs of Corporation X in my example in the intro, I would have simply done the necessary procedures on patients without even thinking of the cost to the employer or the patient or thinking of my potential income. The few hundred bucks I might have made from a couple of thyroid biopsies would have been folded into my fee for caring for the entire population.

If you have past experience with direct physician contracting (or with frustrating up-charges from doctors self-referring), please let us know. We would love to better understand the experiences of our members around this issue.

As the Medical Director of the Kansas Business Group on Health, I’m sometimes asked to weigh in on hot topics that might affect employers or employees. This is a reprint of a blog post from KBGH.

The Robots Are Coming, Part 1

We are mostly techno-optimists here at KBGH. We have talked about the possibility of technology saving the aging primary care workforce by augmenting their skills in certain areas. But if you are a techno-pessimist, you might think more in terms of what automation or robots will do to certain jobs, the way factory automation has decreased the availability of jobs in manufacturing. (Or you may worry about safety because of bias in machines or a Tom Selleck-Runaway style robot rebellion. Great movie with Wichita native Kirstie Alley. I digress.)

My training is in endocrinology and metabolism, disorders of the finely tuned feedback loops of chemical messengers in the body. About half of most endocrinologists’ practices is the care of diabetes mellitus, a collection of metabolic defects that cause excess sugar to build up in the blood and cause blindness, kidney disease, and nerve damage, among other devastating problems. When I was in training in the mid-aughts, a big part of my day was spent managing insulin pumps, small pager-sized devices worn by some diabetic patients that deliver precise doses of insulin to meet their dietary and exercise patterns. My job was to observe blood glucose levels the patients took from fingersticks and coach patients on how to change their pump settings. For all their sophistication, insulin pumps were still pretty manual.

In the last few years, though, a new type of insulin pump has emerged. We call them “closed-loop” devices because, when paired with an implanted sensor that constantly tracks the patient’s blood sugar levels, the pumps can make adjustments to insulin infusion rates without the wearer even being involved. For now, the automation in the devices is mostly confined to rates of insulin infusion when the wearer is not eating or exercising. But pumps that can detect food intake and activity and make rapid adjustments are just around the corner. Insulin pumps will eventually use artificial intelligence, complex intelligence uninvolved with messy human emotionality or consciousness, to make adjustments in the background that are seemingly unrelated to our traditional understanding of diet, exercise, or adherence to therapy. Accidentally load your insulin pump with insulin that is slightly out of date and less potent than last week’s supply? The machine may detect it and adjust your rates of infusion to make up the difference. Have a family tragedy that increases your stress hormone levels, causing blood sugars to spike? The insulin pump’s “brain” may be able to detect this and bring your sugars back to normal without your input or recognition.

And this is just the tip of the iceberg in terms of medical technology. Already “decision support systems,” like the alert your doctor gets through her electronic health record to make sure you get your cancer screenings, show small, persistent improvements in overall care. And as we touched on in previous blog posts, robots have proved themselves to be superior to humans in a range of medical tasks, from finding diabetic eye disease to detecting bleeding in brains on CT scans.

All this will require a cultural shift. Often patients express frustration at having “only seen the PA” when they have gone to the doctor, in spite of ample evidence that physicians’ assistants and nurse practitioners provide excellent care, sometimes exceeding the quality of care of physicians in trials. Our culture currently places value on face-to-face time with the physician. And Americans are anxious about the potential safety of driverless cars in spite of the fact that human-driven cars currently kill more than 30,000 people a year. So how will we respond to robots guiding certain potentially high-risk parts of our care like insulin adjustment or detection of bleeding in radiology studies? Maybe we will give them the same brush-off we sometimes give PAs. Or maybe we will accept their input the way we have accepted advertising algorithms from Facebook and Google. It is completely possible that medical professionals will resent medical robots the way we resent automation for taking away factory jobs. To tiptoe into these ideas we will talk about a potential regulatory framework next week.

As the Medical Director of the Kansas Business Group on Health I’m sometimes asked to weigh in on hot topics that might affect employers or employees. This is a reprint of a blog post from KBGH.

Examining Executive Physicals

As the Medical Director of the Kansas Business Group on Health I’m sometimes asked to weigh in on hot topics that might affect employers or employees. This is a reprint of a blog post from KBGH:

Fifteen years ago it was common to see parked semi trucks with CT scanners in the trailer, advertising “whole-body CT scans” as a preventive measure. Thankfully the trend eventually petered out. I can’t find reliable information on why the practice died. It’s possible that the worried segment of the population simply all had their CTs done, and no one else was willing to pay. But from a medical safety perspective, I hope the practice died because people–patients, regulators, or others–decided that the risk of “false positive” tests, with their necessary biopsies and follow-up testing, all of which carries its own risk, was not justified by the small chance of finding a potentially treatable abnormality. Or people simply decided they didn’t want the relatively large radiation dose (a whole-body CT exposes a person to ~15 mSv radiation, roughly a tenth of the exposure of Hiroshima survivors).

But the practice of whole-body CT scans lives on in the tiny corner of the market known as “executive physicals.”

In a recent paper in JAMA, Deborah Korenstein, Maha Mamoor, and Peter Bach used a combination of internet searching and phone calls to identify highly ranked hospitals offering executive physicals. Executive physicals at these prestigious institutions routinely offered:

  • Electrocardiograms (USPSTF grade D or I for low-risk patients)

  • Chest x-rays (not addressed at all by the USPSTF, but not generally paid for by any insurance company in asymptomatic patients)

  • Pulmonary function testing (USPSTF grade D for asymptomatic patients), and

  • You guessed it: whole-body CT scans.

Unnecessary testing has downsides

The unnecessary testing of anyone–let alone your most highly-paid employees–is a three-headed spear. First, the exams themselves are expensive: around $5,000 each. Second, much of the testing that is unsupported by evidence is likely a waste of money, as we’ve discussed in a previous post, especially since your highly paid professionals are likely to outlive your other employees based on their income alone. But maybe more important is the potential real harm done by unnecessary testing.

A well-known example of this comes from South Korea. That country’s national health insurance program initiated an aggressive cancer screening program in 1999 that screened for breast, cervical, colon, gastric, and liver cancers, mostly free of charge. With certain cancers this is a potentially good idea, even though cancer screening doesn’t seem to make people live longer as a whole. But patients in South Korea were frequently offered thyroid cancer screening with neck ultrasound as an optional add-on for a modest cash price.

By 2011, the rate of thyroid cancer diagnoses in South Korea had jumped 15-fold. This was not because of a new toxin in South Korean drinking water or because of radiation exposure. The entire increase was due to the new detection and diagnosis of “papillary” thyroid cancers that were too small and slow-growing to be felt on physical examination, but were easily detected with ultrasound testing. Because they were small and slow-growing the cancers were also unlikely to ever kill the patients in whom they were discovered.

So what was the downside? All the surgeries to remove cancerous thyroids had consequences (in addition to the surgery’s ~$5,000 cost). In addition to thousands of people who now needed to be on a daily thyroid hormone pill for life, South Korean patients experienced a huge increase in common complications of the surgery: two percent experienced permanent hoarseness due to paralysis of one of the vocal cords, and a whopping eleven percent now needed to take high-potency vitamin D and high-dose calcium multiple times a day for the rest of their lives to prevent muscle cramping because of damage to the calcium-controlling parathyroid glands that lie next to the thyroid.

This might be acceptable if a significant number of years were added to patients’ lives as a result of this. But that has not happened. A person in South Korea has the exact same (very small) chance of dying of thyroid cancer now as she did before this movement. That is to say, all this testing had only downside; there was no upside.

So the next time your company is negotiating the health benefits of its executives it might be worth asking what evidence supports any additional testing offered to C-suite folks. It may cost more than you think.

Health literacy is not just important for C-suite individuals.  Considering that only 12% of Americans having proficient health literacy, and that health-illiterate people spend 80% more on healthcare than their health-literate counterparts, it’s crucial to educate your employees!  The Kansas Business Group on Health offers discounts on resources to educate you employees on how to be better consumers of healthcare.